Editas Medicine, Inc. (0IFK.L)
| Previous close | 7.00 |
| Open | 7.86 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 7.51 - 8.55 |
| 52-week range | 6.49 - 14.12 |
| Volume | |
| Avg. volume | 2,719 |
| Market cap | 3.817M |
| Beta (5Y monthly) | 1.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.73 |
| Earnings date | 31 Oct 2023 - 06 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Motley FoolWhy Editas Medicine Stock Is Soaring Today
What happened Shares of Editas Medicine (NASDAQ: EDIT) were soaring 11.2% higher as of 10:41 a.m. ET on Friday after vaulting as much as 24% earlier in the day. The big gain came after Stifel analyst Dae Gon Ha upgraded the stock from hold to buy.
Motley Fool1 Gene Editing Stock to Buy Now, and 1 to Sell
In our modern age, the power of gene editing is undeniable. One stock with an encouraging outlook is gene-editing biotech Caribou Biosciences (NASDAQ: CRBU). The Berkeley, California-based company has two cancer programs in phase 1 trials: one for relapsed or refractory B-cell non-Hodgkin lymphoma, and another to treat relapsed or refractory multiple myeloma.
ZacksUltragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock?
Ultragenyx (RARE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
